{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:45:18Z","timestamp":1752230718933,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/n\/a","name":"an Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26462167"],"award-info":[{"award-number":["26462167"]}],"id":[{"id":"10.13039\/n\/a","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/n\/a","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K10838"],"award-info":[{"award-number":["17K10838"]}],"id":[{"id":"10.13039\/n\/a","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12640-021-00373-7","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T10:03:16Z","timestamp":1621245796000},"page":"1300-1309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["FTY720 Exacerbates Blood\u2013Brain Barrier Dysfunction Induced by IgG Derived from Patients with NMO and MOG Disease"],"prefix":"10.1007","volume":"39","author":[{"given":"Shunsuke","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7945-9719","authenticated-orcid":false,"given":"Shinsuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"373_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","volume":"7","author":"NJ Abbott","year":"2006","unstructured":"Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41\u201353. https:\/\/doi.org\/10.1038\/nrn1824","journal-title":"Nat Rev Neurosci"},{"key":"373_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-020-02023-z","author":"A Ahmad","year":"2020","unstructured":"Ahmad A, Patel V, Xiao J, Khan MM (2020) The role of neurovascular system in neurodegenerative diseases. Mol Neurobiol. https:\/\/doi.org\/10.1007\/s12035-020-02023-z","journal-title":"Mol Neurobiol"},{"key":"373_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.it.2015.09.008","volume":"36","author":"L Brimberg","year":"2015","unstructured":"Brimberg L, Mader S, Fujieda Y, Arinuma Y, Kowal C, Volpe BT, Diamond B (2015) Antibodies as Mediators of Brain Pathology. Trends Immunol 36:709\u2013724. https:\/\/doi.org\/10.1016\/j.it.2015.09.008","journal-title":"Trends Immunol"},{"key":"373_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","volume":"168","author":"J Camm","year":"2014","unstructured":"Camm J, Hla T, Bakshi R, Brinkmann V (2014) Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J 168:632\u2013644. https:\/\/doi.org\/10.1016\/j.ahj.2014.06.028","journal-title":"Am Heart J"},{"key":"373_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.chemphyslip.2015.08.004","volume":"191","author":"SM Camp","year":"2015","unstructured":"Camp SM et al (2015) Pulmonary endothelial cell barrier enhancement by novel FTY720 analogs: methoxy-FTY720, fluoro-FTY720, and beta-glucuronide-FTY720. Chem Phys Lipids 191:16\u201324. https:\/\/doi.org\/10.1016\/j.chemphyslip.2015.08.004","journal-title":"Chem Phys Lipids"},{"key":"373_CR6","first-page":"213","volume":"12","author":"J Chun","year":"2011","unstructured":"Chun J, Brinkmann V (2011) A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12:213\u2013228","journal-title":"Discov Med"},{"key":"373_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1172\/JCI88720","volume":"127","author":"BP Daniels","year":"2017","unstructured":"Daniels BP et al (2017) Regional astrocyte IFN signaling restricts pathogenesis during neurotropic viral infection. J Clin Invest 127:843\u2013856. https:\/\/doi.org\/10.1172\/JCI88720","journal-title":"J Clin Invest"},{"key":"373_CR8","doi-asserted-by":"publisher","unstructured":"Dargahi N, Katsara M, Tselios T, Androutsou ME, Courten de\u00a0M,\u00a0Matsoukas J, Apostolopoulos V (2017) Multiple sclerosis: immunopathology and treatment update Brain Sci 7.\u00a0https:\/\/doi.org\/10.3390\/brainsci7070078","DOI":"10.3390\/brainsci7070078"},{"key":"373_CR9","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","volume":"69","author":"SR Hinson","year":"2007","unstructured":"Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA (2007) Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69:2221\u20132231. https:\/\/doi.org\/10.1212\/01.WNL.0000289761.64862.ce","journal-title":"Neurology"},{"key":"373_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","volume":"185","author":"A Huwiler","year":"2018","unstructured":"Huwiler A, Zangemeister-Wittke U (2018) The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. Pharmacol Ther 185:34\u201349. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.11.001","journal-title":"Pharmacol Ther"},{"key":"373_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/ijms17030273","volume":"17","author":"M Jasiak-Zatonska","year":"2016","unstructured":"Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, Kozubski W (2016) The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives. Int J Mol Sci 17:273. https:\/\/doi.org\/10.3390\/ijms17030273","journal-title":"Int J Mol Sci"},{"key":"373_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.drudis.2006.06.008","volume":"11","author":"J Kraus","year":"2006","unstructured":"Kraus J, Oschmann P (2006) The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today 11:755\u2013762. https:\/\/doi.org\/10.1016\/j.drudis.2006.06.008","journal-title":"Drug Discov Today"},{"key":"373_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/1352458508088940","volume":"14","author":"J Kraus","year":"2008","unstructured":"Kraus J et al (2008) Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro. Mult Scler 14:843\u2013852. https:\/\/doi.org\/10.1177\/1352458508088940","journal-title":"Mult Scler"},{"key":"373_CR14","doi-asserted-by":"publisher","unstructured":"Lana-Peixoto\u00a0MA,\u00a0Talim\u00a0N\u00a0(2019) Neuromyelitis optica spectrum disorder and anti-MOG syndromes Biomed 7.\u00a0https:\/\/doi.org\/10.3390\/biomedicines7020042","DOI":"10.3390\/biomedicines7020042"},{"key":"373_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473\u2013477. https:\/\/doi.org\/10.1084\/jem.20050304","journal-title":"J Exp Med"},{"key":"373_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/01.wnl.0000343001.36493.ae","volume":"72","author":"SM Magana","year":"2009","unstructured":"Magana SM et al (2009) Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 72:712\u2013717. https:\/\/doi.org\/10.1212\/01.wnl.0000343001.36493.ae","journal-title":"Neurology"},{"key":"373_CR17","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.4049\/jimmunol.1301296","volume":"191","author":"MC Mayer","year":"2013","unstructured":"Mayer MC et al (2013) Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 191:3594\u20133604. https:\/\/doi.org\/10.4049\/jimmunol.1301296","journal-title":"J Immunol"},{"key":"373_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1352458511431973","volume":"18","author":"JH Min","year":"2012","unstructured":"Min JH, Kim BJ, Lee KH (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 18:113\u2013115. https:\/\/doi.org\/10.1177\/1352458511431973","journal-title":"Mult Scler"},{"key":"373_CR19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/brain\/awm047","volume":"130","author":"T Misu","year":"2007","unstructured":"Misu T et al (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130:1224\u20131234. https:\/\/doi.org\/10.1093\/brain\/awm047","journal-title":"Brain"},{"key":"373_CR20","doi-asserted-by":"publisher","first-page":"1365175","DOI":"10.1155\/2018\/1365175","volume":"2018","author":"SH Mohseni","year":"2018","unstructured":"Mohseni SH, Skejoe HPB, Wuerfel J, Paul F, Reindl M, Jarius S, Asgari N (2018) Leptomeningeal and intraparenchymal blood barrier disruption in a MOG-IgG-positive patient. Case Rep Neurol Med 2018:1365175. https:\/\/doi.org\/10.1155\/2018\/1365175","journal-title":"Case Rep Neurol Med"},{"key":"373_CR21","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200224112534","author":"Y Morofuji","year":"2020","unstructured":"Morofuji Y, Nakagawa S (2020) Drug development for central nervous system diseases using in vitro blood-brain barrier models and drug repositioning. Curr Pharm Des. https:\/\/doi.org\/10.2174\/1381612826666200224112534","journal-title":"Curr Pharm Des"},{"key":"373_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.pupt.2011.01.017","volume":"24","author":"HC Muller","year":"2011","unstructured":"Muller HC et al (2011) The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. Pulm Pharmacol Ther 24:377\u2013385. https:\/\/doi.org\/10.1016\/j.pupt.2011.01.017","journal-title":"Pulm Pharmacol Ther"},{"key":"373_CR23","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12035-019-01844-x","volume":"57","author":"S Nakagawa","year":"2020","unstructured":"Nakagawa S, Aruga J (2020) Sphingosine 1-phosphate signaling is involved in impaired blood-brain barrier function in ischemia-reperfusion injury. Mol Neurobiol 57:1594\u20131606. https:\/\/doi.org\/10.1007\/s12035-019-01844-x","journal-title":"Mol Neurobiol"},{"key":"373_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.neuint.2008.12.002","volume":"54","author":"S Nakagawa","year":"2009","unstructured":"Nakagawa S et al (2009) A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 54:253\u2013263. https:\/\/doi.org\/10.1016\/j.neuint.2008.12.002","journal-title":"Neurochem Int"},{"key":"373_CR25","doi-asserted-by":"publisher","unstructured":"Nakajima H, Hosokawa T, Doi Y, Ikemoto T, Ishida S, Kimura F, Hanafusa T (2012) Interferon-beta1b increases Th2 response in neuromyelitis optica. Int J Mol Sci 13:12213\u201312223.\u00a0https:\/\/doi.org\/10.3390\/ijms131012213","DOI":"10.3390\/ijms131012213"},{"key":"373_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","volume":"10","author":"MC Papadopoulos","year":"2014","unstructured":"Papadopoulos MC, Bennett JL, Verkman AS (2014) Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol 10:493\u2013506. https:\/\/doi.org\/10.1038\/nrneurol.2014.141","journal-title":"Nat Rev Neurol"},{"key":"373_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.msard.2018.09.011","volume":"26","author":"M Popiel","year":"2018","unstructured":"Popiel M, Psujek M, Bartosik-Psujek H (2018) Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate. Mult Scler Relat Disord 26:204\u2013206. https:\/\/doi.org\/10.1016\/j.msard.2018.09.011","journal-title":"Mult Scler Relat Disord"},{"key":"373_CR28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molmed.2015.03.006","volume":"21","author":"B Prager","year":"2015","unstructured":"Prager B, Spampinato SF, Ransohoff RM (2015) Sphingosine 1-phosphate signaling at the blood-brain barrier. Trends Mol Med 21:354\u2013363. https:\/\/doi.org\/10.1016\/j.molmed.2015.03.006","journal-title":"Trends Mol Med"},{"key":"373_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/TCRM.S53285","volume":"10","author":"S Ruggieri","year":"2014","unstructured":"Ruggieri S, Tortorella C, Gasperini C (2014) Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag 10:229\u2013239. https:\/\/doi.org\/10.2147\/TCRM.S53285","journal-title":"Ther Clin Risk Manag"},{"key":"373_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jneuroim.2009.07.014","volume":"215","author":"L Sabater","year":"2009","unstructured":"Sabater L et al (2009) Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol 215:31\u201335. https:\/\/doi.org\/10.1016\/j.jneuroim.2009.07.014","journal-title":"J Neuroimmunol"},{"key":"373_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/25785826.2018.1531190","volume":"41","author":"F Shimizu","year":"2018","unstructured":"Shimizu F, Nishihara H, Kanda T (2018) Blood-brain barrier dysfunction in immuno-mediated neurological diseases. Immunol Med 41:120\u2013128. https:\/\/doi.org\/10.1080\/25785826.2018.1531190","journal-title":"Immunol Med"},{"key":"373_CR32","doi-asserted-by":"publisher","unstructured":"Shimizu F et al (2017) Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica Sci Transl Med 9.\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aai9111","DOI":"10.1126\/scitranslmed.aai9111"},{"key":"373_CR33","doi-asserted-by":"publisher","first-page":"e92872","DOI":"10.1371\/journal.pone.0092872","volume":"9","author":"F Shimizu","year":"2014","unstructured":"Shimizu F et al (2014) Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier. PLoS ONE 9:e92872. https:\/\/doi.org\/10.1371\/journal.pone.0092872","journal-title":"PLoS ONE"},{"key":"373_CR34","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","volume":"75","author":"J Shimizu","year":"2010","unstructured":"Shimizu J et al (2010) IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75:1423\u20131427. https:\/\/doi.org\/10.1212\/WNL.0b013e3181f8832e","journal-title":"Neurology"},{"key":"373_CR35","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","volume":"4","author":"Y Takeshita","year":"2017","unstructured":"Takeshita Y et al (2017) Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 4:e311. https:\/\/doi.org\/10.1212\/NXI.0000000000000311","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"373_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/jnnp-2013-305907","volume":"85","author":"A Tasaki","year":"2014","unstructured":"Tasaki A et al (2014) Autocrine MMP-2\/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry 85:419\u2013430. https:\/\/doi.org\/10.1136\/jnnp-2013-305907","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"373_CR37","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","volume":"181","author":"T Vincent","year":"2008","unstructured":"Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, Antel JP (2008) Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 181:5730\u20135737. https:\/\/doi.org\/10.4049\/jimmunol.181.8.5730","journal-title":"J Immunol"},{"key":"373_CR38","doi-asserted-by":"publisher","first-page":"e6040","DOI":"10.7759\/cureus.6040","volume":"11","author":"Y Warabi","year":"2019","unstructured":"Warabi Y, Takahashi T, Isozaki E (2019) Dimethyl Fumarate Was Ineffective but Not Harmful for a Patient with Myelin Oligodendrocyte Glycoprotein Antibody Disease. Cureus 11:e6040. https:\/\/doi.org\/10.7759\/cureus.6040","journal-title":"Cureus"},{"key":"373_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","volume":"27","author":"Y Wu","year":"2019","unstructured":"Wu Y, Zhong L, Geng J (2019) Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat Disord 27:412\u2013418. https:\/\/doi.org\/10.1016\/j.msard.2018.12.002","journal-title":"Mult Scler Relat Disord"},{"key":"373_CR40","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","volume":"266","author":"R Wynford-Thomas","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V (2019) Neurological update: MOG antibody disease. J Neurol 266:1280\u20131286. https:\/\/doi.org\/10.1007\/s00415-018-9122-2","journal-title":"J Neurol"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-021-00373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12640-021-00373-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-021-00373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T04:27:02Z","timestamp":1626064022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12640-021-00373-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["373"],"URL":"https:\/\/doi.org\/10.1007\/s12640-021-00373-7","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"type":"print","value":"1029-8428"},{"type":"electronic","value":"1476-3524"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"31 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}